The histological diagnosis of metastases to the breast from extramammary malignancies

Journal of Clinical Pathology

Volumn 60, Issue 12, 2007, Pages 1333-1341

  Lee, Andrew H S ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MELAN A; PROTEIN S 100; THYROID TRANSCRIPTION FACTOR 1;

BREAST CARCINOMA; BREAST METASTASIS; CANCER DIAGNOSIS; CLINICAL FEATURE; ELASTOSIS; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MAMMOGRAPHY; MELANOMA; NEPHROBLASTOMA; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELANOMA; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 36548998684     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.046078     Document Type: Review

References (93)

1. Toombs BD, Kalisher L. Metastatic disease to the breast: clinical, pathologic, and radiographic features. Am J Roentgenol 1977;129:673-6.
2. Chaignaud B, Hall TJ, Powers C, et al. Diagnosis and natural history of extramammary tumors metastatic to the breast. J Am Coll Surg 1994;179:49-53.
3. Vizcaino I, Torregrosa A, Higueras V, et al. Metastasis to the breast from extramammary malignancies: a report of four cases and a review of literature. Eur Radiol 2001;11:1659-65.
4. Hajdu SI, Urban JA. Cancers metastatic to the breast. Cancer 1972;29:1691-6.
5. McIntosh IH, Hooper AA, Millis RR, et al. Metastatic carcinoma within the breast. Clin Oncol 1976;2:393-401.
6. McCrea ES, Johnston C, Haney PJ. Metastases to the breast. Am J Roentgenol 1983;141:685-90.
7. Alvarado Cabrero I, Carrera Alvarez M, Perez Montiel D, et al. Metastases to the breast. Eur J Surg Oncol 2003;29:854-5.
8. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. Cancer 1950;3:74-84.
9. Georgiannos SN, Aleong JC, Goode AW, et al. Secondary neoplasms of the breast: a survey of the 20th century. Cancer 2001;92:2259-66.
10. Alva S, Shetty-Alva N. An update of tumor metastasis to the breast data.[letter]. Arch Surg 1999;134:450.
11. Rogers DA, Lobe TE, Rao BN, et al. Breast malignancy in children. J Pediatric Surg 1994;29:48-51.
12. Pettinato G, Manivel JC, Kelly DR, et al. Lesions of the breast in children exclusive of typical fibroadenoma and gynecomastia. A clinicopathologic study of 113 cases. Pathol Annu 1989;24:295-328.
13. Sandison AT. Metastatic tumours in the breast. Br J Surg 1959;47:54-8.
14. Amichetti M, Perani B, Boi S. Metastases to the breast from extramammary malignancies. Oncology 1990;47:257-60.
15. Vergier B, Trojani M, de Mascarel I, et al. Metastases to the breast: differential diagnosis from primary breast carcinoma. J Surg Oncol 1991;48:112-16.
16. Silverman EM, Oberman HA. Metastatic neoplasms in the breast. Surg Gynecol Obstet 1974;138:26-8.
17. Nielsen M, Andersen JA, Henriksen FW, et al. Metastases to the breast from extramammary carcinomas. APMIS 1981;89:251-6.
18. Lee SH, Park JM, Kook SH, et al. Metastatic tumors to the breast: mammographic and ultrasonographic findings. J Ultrasound Med 2000;19:257-62.
19. Sneige N, Zachariah S, Fanning TV, et al. Fine-needle aspiration cytology of metastatic neoplasms in the breast. Am J Clin Pathol 1989;92:27-35.
20. Bohman LG, Bassett LW, Gold RH, et al. Breast metastases from extramammary malignancies. Radiology 1982;144:309-12.
21. Harris GC, Denley HE, Pinder SE, et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 2003;27:11-15.
22. Lee AHS, Gillett CE, Ryder K, et al. Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 2006;48:692-701.
23. Badve S. Other malignant lesions of the breast. In: O'Malley FP, Pinder SE, eds. Breast pathology. Churchill Livingstone, 2006:283-301.
24. Chu PG, Weiss IM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-39.
25. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 2002;38:758-63.
26. Tot T. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases. Ann Diagn Pathol 1999;3:350-6.
27. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-71.
28. Pinkus GS, Kurtin PJ. Epithelial membrane antigen-a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol 1985;16:929-40.
29. Gillett CE, Bobrow LG, Millis RR. S100 protein in human mammary tissue-immunoreactivity in breast carcinoma, including Paget's disease of the nipple, and value as a marker of myoepithelial cells. J Pathol 1990;160:19-24.
30. Dwarakanath S, Lee AKC, Delellis RA, et al. S-100 protein positivity in breast carcinomas: a potential pitfall in diagnostic immunohistochemistry. Hum Pathol 1987;18:1144-8.
31. Robertson JFR, Ellis IO, Bell J, et al. Carcinoembryonic antigen immunocytochemistry in primary breast cancer. Cancer 1989;64:1638-45.
32. Zafrani B, Aubriot MH, Mouref E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000;37:536-45.
33. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-96.
34. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123:21-7.
35. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-72.
36. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996;29:233-40.
37. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol 2006;14:83-7.
38. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989;20:281-7.
39. Lagendijk JH, Mullink H, van Diest PJ, et al. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999;52:283- 90.
40. Recine MA, Deavers MT, Middleton LP, et al. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol 2004;28:1646- 51.
41. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001;116:246-52.
42. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002;117:745-50.
43. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004;12:122-6.
44. Tomos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005;29:1482-9.
45. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
46. Pettinato G, Manivel G, Panico L, et al. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol 2004;121:857-66.
47. Loy TS, Quesenberry JT, Sharp SC. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol 1992;98:175-9.
48. Frierson HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-9.
49. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2004;27:1418-28.
50. Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology 2000;36:387-402.
51. Miettinen M, Fernandez M, Franssifa K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001;25:205-11.
52. Granter SR, Weilbaecher KN, Quigley C, et al. Role far microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol 2002;10:47-51.
53. Gajjar NA, Cochran Al, Binder SW. Is MAGE-1 expression in metastatic malignant melanomas really helpful? Am J Surg Pathol 2004;28:883-8.
54. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol 1997;28:1373-8.
55. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000;36:415- 20.
56. Shin SJ, DeLellis RA, Rosen PP. Small cell carcinoma of the breast-additional immunohistochemical studies. Am J Surg Pathol 2001;25:831-2.
57. Shin SJ, DeLellis RA, Ying L, et al. Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol 2000;24:1231-8.
58. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996;9:445-52.
59. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
60. Fulford LG, Easton DF, Reis-Filhi JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma. Histopathology 2006;49:22-34.
61. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
62. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000;36:8-16.
63. Nadji M, Tabei SZ, Castro A, et al. Prostatic origin of tumors. An immunohistochemical study. Am J Clin Pathol 1980;73:735-9.
64. Varma M, Morgan M, Jasani B, et al. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol 2002;118:202-7.
65. Bassily NH, Vallorosi G, Akdas G, et al. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol 2000;113:383-8.
66. van Krieken JHJM. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol 1993;17:410-14.
67. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000;17:184-93.
68. Gatalica Z, Norris BA, Kovatich AJ. Immunohistochemical localization of prostate-specific antigen in ductal epithelium of male breast. Potential diagnostic pitfall in patients with gynecomastia. Appl Immunohistochem Mol Morphol 2000;8:158-61.
69. Kidwai N, Gong Y, Sun X, et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 2004;6:R18-23.
70. Carder PJ, Speirs V, Ramsdale J, et al. Expression of prostate specific antigen in male breast cancer. J Clin Pathol 2005;58:69-71.
71. Goldstein NS, Long A, Kuan SF, et al. Colon signet ring cell adenocarcinoma: immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. Appl Immunohistochem Mol Morphol 2000;8:183-8.
72. van Velthuysen MLF, Taal BG, van der Hoeven JJM, et al. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology 2005;46:153-7.
73. O'Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med 2005;129:338-47.
74. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-19.
75. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10.
76. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. Am J Clin Pathol 1999;111:539-43.
77. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonarantibody 'Renal Cell Carcinoma Marker'. Am J Surg Pathol 2001;25:1485-92.
78. Iwaya K, Ogawa H, Izumi M, et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002;440:589-93.
79. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-82.
80. Langner C, Ratschek M, Rehak P, et al. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 2004;171:611-14.
81. Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002;10:332-8.
82. Cai YC, Banner B, Glickman J, et al. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2001;32:1087-93.
83. Sapino A, Righi L, Cassoni P, et al. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol 2001;14:768-76.
84. Viale G, Doglioni C, Gambacorta M, et al. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer 1992;70:2268-77.
85. Dunne B, Lee AHS, Pinder SE, et al. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol 2003;34:1009-15.
86. Hugh JC, Jackson FI, Hanson J, et al. Primary breast lymphoma. An immunohistologic study of 20 new cases. Cancer 1990;66:2602-11.
87. Domchek SM, Hecht JL, Fleming MD, et al. Lymphomas of the breast: primary and secondary involvement. Cancer 2002;94:6-13.
88. Duncan VE, Reddy WB, Jhala NC, et al. Non-Hodgkin's lymphoma of the breast: a review of 18 primary and secondary cases. Ann Diagn Pathol 2006;10:144-8.
89. Aguilera NSI, Tavassoli FA, Chu WS, et al. T-cell lymphoma presenting in the breast: a histologic, immunophenotypic and molecular genetic study or four cases. Mod Pathol 2000;13:599-605.
90. Shanks JH, Banerjee SS. VS38 immunostaining in melanocyte lesions. J Clin Pathol 1996;49:205-7.
91. Banerjee SS, Shanks JH, Hasleton PS. VS38 immunostaining in neuroendocrine tumours. Histopathology 1997;30:256-9.
92. Kambham N, Kong C, Longacre TA, et al. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005;13:304-10.
93. Austen J. Emma. London: Penguin, 1994.